Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
Phase III Randomized Study of Crenolanib versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects with FLT3 Mutated Acute Myeloid Leukemia
A Phase I, Parallel, Open-Label Study of the Safety and Tolerability, Pharmacokinetics, and Antileukemic Activity of ASTX660 as a Single Agent and in Combination with ASTX727 in Subjects with Acute Myeloid Leukemia
Phase I/II Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells VCAR33 in Patients with Relapsed or Refractory Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation
Study Type: Treatment
Phase: I/II
NCTID: NCT05984199
Principal Investigator:
Muhammad Umair Mushtaq
A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation versus Conventional Care in Older Subjects with Active, Relapsed or Refractory Acute Myeloid Leukemia.
Stopping Tyrosine Kinase Inhibitors TKI to Assess Treatment-Free Remission TFR in Pediatric Chronic Myeloid Leukemia - Chronic Phase CML-CP
Study Type: Treatment
Phase: Feasibility/Pilot
NCTID: NCT03817398
Principal Investigator:
Keith August
An Open-Label Feasibility Study to Assess the Safety and Pharmacokinetics of Enasidenib in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia R/R-AML with an Isocitrate Dehydrogenase-2 IDH2 Mutation
Study Type: Treatment
Phase: Feasibility/Pilot
NCTID: NCT04203316
Principal Investigator:
Kevin Ginn
A Phase IIA, Open-label, Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of BP1001 a Liposomal Grb2 Antisense Oligonucleotide in Combination with Venetoclax plus Decitabine in Patients with Acute Myeloid Leukemia AML Who Are Ineligible for Intensive Induction Therapy
A Phase III, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Azacitidine versus Physician?s Choice of Venetoclax in Combination with Azacitidine or Intensive Chemotherapy in Previously Untreated Patients with TP53 Mutant Acute Myeloid Leukemia.
Study Type: Treatment
Phase: III
NCTID: NCT04778397
Principal Investigator:
Jesus Gonzalez Lugo
A PHASE 1 STUDY OF REVUMENIB, AZACITIDINE, AND VENETOCLAX AND IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA
Study Type: Treatment
Phase: I
NCTID: NCT06177067
Principal Investigator:
Keith August